Issues with Antibodies for GSK-3 Localization
Author Information
Author(s): Victor M. Campa, Robert M. Kypta
Primary Institution: Center for Cooperative Research in Biosciences (CIC bioGUNE), Bizkaia Technology Park, Spain; Department of Surgery and Cancer, Imperial College London, UK
Hypothesis
The specificity of commercially available anti-phosphorylated GSK-3 antibodies in immunocytochemistry has not been adequately validated.
Conclusion
The study highlights the need for caution when using phosphospecific antibodies to determine the localization of GSK-3 in cells.
Supporting Evidence
- Antibodies raised to phosphorylated GSK-3 showed nonspecific staining patterns.
- Gene silencing confirmed the reduction of GSK-3 levels in transfected cells.
- The study found that some antibodies recognized unidentified proteins in mitotic cells.
Takeaway
This study shows that some antibodies used to detect GSK-3 might actually recognize other proteins, which can lead to misleading results.
Methodology
The study used RNA interference to silence GSK-3 isoforms in prostate cancer cells and examined the specificity of various anti-phosphorylated GSK-3 antibodies through western blotting and immunofluorescence.
Potential Biases
Potential bias due to reliance on commercially available antibodies that may not have been thoroughly validated for all applications.
Limitations
The study primarily focuses on a limited number of antibodies and cell types, which may not represent all contexts.
Participant Demographics
22Rv1 prostate cancer cells were used in the study.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website